Abbott's Core Businesses Thrive Despite Macroeconomic Issues
https://www.zacks.com/stock/news/2327754/abbott-s-core-businesses-thrive-despite-macroeconomic-issues?cid=CS-ZC-FT-analyst_blog|zer_report_update-2327754
Aug 27, 2024 - ABT is particularly gaining from the strong adoption of its market leading systems and demand for testing that takes place in a variety of settings.
0
This Is Great News for Medtronic, but Is It Time to Buy the Stock?
https://www.fool.com/investing/2024/08/26/great-news-for-medtronic-investors-time-to-buy/?source=iedfolrf0000001
Aug 26, 2024 - This MedTech leader is back on track with profitable growth.
0
3 Unstoppable Dividend Stocks to Buy Right Now
https://www.fool.com/investing/2024/08/25/3-unstoppable-dividend-stocks-to-buy-right-now/?source=iedfolrf0000001
Aug 25, 2024 - These stocks are the A-team for income investors.
0
Abbott (ABT) Gets FDA Approval for Aspirin-Free HeartMate 3 Regimen
https://www.zacks.com/stock/news/2326206/abbott-abt-gets-fda-approval-for-aspirin-free-heartmate-3-regimen?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2326206
Aug 23, 2024 - Abbott's (ABT) labeling update, exclusively for patients with a HeartMate 3 heart pump, secures the FDA's approval.
0
Abbott (ABT) Advances While Market Declines: Some Information for Investors
https://www.zacks.com/stock/news/2326009/abbott-abt-advances-while-market-declines-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2326009
Aug 22, 2024 - Abbott (ABT) closed the most recent trading day at $112.10, moving +0.64% from the previous trading session.
0
Looking for Safe Dividend Income? These 3 Stocks Have Rock-Solid Payouts.
https://www.fool.com/investing/2024/08/17/looking-for-safe-dividend-income-these-3-stocks-ha/?source=iedfolrf0000001
Aug 17, 2024 - These stocks pay above-average yields, and their dividend income could rise higher in the future.
0
Medtronic (MDT) Progresses in CGM With New Approval, Alliance
https://www.zacks.com/stock/news/2322671/medtronic-mdt-progresses-in-cgm-with-new-approval-alliance?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2322671
Aug 15, 2024 - The FDA approval for Medtronic's (MDT) Simplera CGM sets the stage for further regulatory submissions of the updated InPen smart insulin pen app.
0
Abbott Up 7.7% Post Q2 Earnings: Should You Buy ABT Stock?
https://www.zacks.com/stock/news/2321482/abbott-up-7-7-post-q2-earnings-should-you-buy-abt-stock?cid=CS-ZC-FT-analyst_blog|most_popular_stocks-2321482
Aug 13, 2024 - Abbott's (ABT) strong growth projection for 2024 is an indication that the stock will be able to sustain the positive momentum through the rest of the year.
0
Charles River (CRL) Q2 Earnings Beat Estimates, 2024 View Down
https://www.zacks.com/stock/news/2318347/charles-river-crl-q2-earnings-beat-estimates-2024-view-down?cid=CS-ZC-FT-analyst_blog|earnings_article-2318347
Aug 07, 2024 - Charles River's (CRL) Manufacturing business segments report organic revenue growth, partially offset by lower revenues in the DSA and RMS segments.
0
Waters (WAT) Q2 Earnings & Sales Beat Estimates, Fall Y/Y
https://www.zacks.com/stock/news/2313398/waters-wat-q2-earnings-sales-beat-estimates-fall-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2313398
Jul 31, 2024 - Waters' (WAT) second-quarter results are hurt by weak end-market momentum and softness in Asia, Americas and Europe.
0